Beware: things are not normal
With markets are all over the place, it is hard for investors to know what to do. But there is a strong chance that the assets that have done well over the last few years won’t do the same over the next few.


This is not a normal environment – and there is no reason to think it should be. The last decade has seen a variety of extraordinary monetary experiments and the last two years have jumped every possible shark. We’ve seen rolling economic shutdowns, a new level of quantitative easing (QE), helicopter money, insanely-low interest rates, the biggest recession ever, and of course, the biggest recovery ever.
We’ve watched vast fortunes being made in tech stocks and in cryptocurrencies – and of course, in housing. Now we have supply crunches, the (fast) return of inflation, a shift in power from capital to labour, and one hell of a pivot from behind-the-curve central banks. With all that in mind you should not be particularly surprised that markets are all over the place, or for that matter that seeing through the noise is tricky.
It is hard to know what to do. However there is one thing it is increasingly clear that you should not do – and that is to retreat to the perceived safety of the assets that have done you well over the last few years. There is a strong chance they won’t do the same over the next few. Which assets do I mean?
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
First up is US stocks and tech stocks in particular. Keeping too many of these, says Ben Inker of GMO, is likely to be the first big mistake investors make in 2022. Their outperformance in 2020 and 2021 cemented the idea that they are the lowest-risk, highest-return version of equities ever – and recent volatility aside, a safe long-term option. But their outperformance has also made the US expensive – and so remarkably unsafe. You would be better, says Inker, to cut your US exposure and move into China and emerging market equities (much cheaper).
Beware frothy valuations
Next is private equity and venture capital. Those worried about the future might see that some institutions have made fortunes here and pile in too. There are all sorts of problems with this (the difficulty of selling private assets in tricky times being an obvious one). But the key thing is price: valuations are “frothy” – too frothy to compensate for the risks. Remember too that the exit route for private equity (the bit where you get the money) is via public markets. If public markets aren’t prepared to pay as much for growth as they were (that’s why tech stocks are falling) private equity valuations obviously have to fall too. This is not a safe place to be.
Third is US bonds. When markets fell in early 2020, US Treasuries were “wonderfully protective.” But the main reason bonds outperform in bad times is because central banks can and do cut rates into the downturn. This option wasn’t available in the likes of Switzerland and Sweden in 2020. The result? Their “previously reliable defensiveness” was no longer available. That may now be the case with Treasuries. They protected you in 2020. They probably won’t in 2022.
Eagle-eyed readers will have noticed something here – the core problem with all these three things is price. A bond can only protect you if it isn’t already horribly overpriced. A very expensive growth stock can only keep making you money if investor perception of the value of that growth doesn’t change. A private equity investment can only make you money if you don’t overpay for it. You can only think that these things are safe if you think their price doesn’t matter. It usually does.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
Merryn Somerset Webb started her career in Tokyo at public broadcaster NHK before becoming a Japanese equity broker at what was then Warburgs. She went on to work at SBC and UBS without moving from her desk in Kamiyacho (it was the age of mergers).
After five years in Japan she returned to work in the UK at Paribas. This soon became BNP Paribas. Again, no desk move was required. On leaving the City, Merryn helped The Week magazine with its City pages before becoming the launch editor of MoneyWeek in 2000 and taking on columns first in the Sunday Times and then in 2009 in the Financial Times
Twenty years on, MoneyWeek is the best-selling financial magazine in the UK. Merryn was its Editor in Chief until 2022. She is now a senior columnist at Bloomberg and host of the Merryn Talks Money podcast - but still writes for Moneyweek monthly.
Merryn is also is a non executive director of two investment trusts – BlackRock Throgmorton, and the Murray Income Investment Trust.
-
New Chase bonus deal takes savings rate to 4.75% – is it worth it?
Chase’s latest savings deal propels it into first place in the best-buy tables, but there are some pitfalls to look out for
By Katie Williams Published
-
Review: Trasierra – a yoga retreat in the Spanish hills
Flora Connell joins a yoga retreat at Trasierra, in the Sierra Morena mountains north of Seville
By Flora Connell Published
-
Why CEOs deserve a pay rise
Opinion The CEOs of big companies often come under fire for being grossly overpaid. But the truth, as per some economists, is the opposite. Do they merit a pay rise?
By Stuart Watkins Published
-
Rolls-Royce stock jumps 15% – could it climb further?
Aircraft-engine group Rolls-Royce’s CEO has been hailed as a hero for spearheading the firm’s recovery. And the future looks bright, says Matthew Partridge
By Dr Matthew Partridge Published
-
The power of private markets
Interview Helen Steers, co-manager of the Pantheon International investment trust, tells MoneyWeek about the vast array of compelling opportunities in private equity
By Andrew Van Sickle Published
-
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success
By Dr Mike Tubbs Published
-
Global investors have overlooked these top tips in emerging markets
Opinion Chris Tennant, co-portfolio manager of Fidelity Emerging Markets, picks three attractive companies in emerging markets
By Chris Tennant Published
-
King Coal has not been dethroned yet — should you buy?
The demand for coal is only growing, yet investors don’t seem to want to take advantage of the opportunity, says Rupert Hargreaves
By Rupert Hargreaves Published
-
It’s time to start buying Europe again, says Merryn Somerset Webb
Opinion Europe's stocks are cheap and the economic backdrop is starting to look cheerier, says Merryn Somerset Webb
By Merryn Somerset Webb Published
-
Prosus to buy Just Eat for €4.1 billion as takeaway boom fades
Food-delivery platform Just Eat has been gobbled up by a Dutch rival. Now there could be further consolidation in the sector
By Dr Matthew Partridge Published